Related Experiment Videos
Industry and regulatory performance in 2012: a year in review
1Strategy Portfolio & Performance, AstraZeneca, Wilmington, Delaware, USA. helen.dowden@astrazeneca.com
Abstract:
2012 was a robust year for new molecular entity (NME) approvals in the major geographic regions. What is behind this apparent improved performance? Has the pharmaceutical industry turned the tide in research and development productivity? In this analysis, we look not only at the number of approvals in 2012 but also at their clinical and market potential. We discuss how changes in the regulatory and reimbursement environment impact current industry performance and how this might evolve.
Related Concept Videos
Drug Control Governance: Regulatory Bodies and Their Impact
Global Regulatory Systems
Drug Regulation
Drug Product Performance: In Vitro–In Vivo Correlation
Interpreting R Charts
An R chart plots the range of subsets of measurements collected from a process. Each point on the chart represents the range—defined as the difference between the maximum and minimum values—of a sample...
Types of Records II: Educational and Administrative Records